Volume 6, Issue 2, June 2018, Page: 30-42
Incidence of Positive Anti-Ro/SSA and Anti-La/SSB Antibodies Among Infants with Prolonged Skin Lesions and Its Relation to Autoimmune Disease in the Mother
Mona Sayed Aly Hassan Makhlouf, Department of Pediatrics, Al Galaa Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Suzan Fahim Ghobashy, Department of Pediatrics, Al Galaa Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Hanan Farouk Mohamed, Department of Clinical Pathology, Al Galaa Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Ikram Idris Alyan, Department of Rheumatology and Rehabilitation, Al Galaa Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Fawzy Aly Abualfadl, Department of Dermatology, Ahmed Maher Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Received: Jun. 1, 2018;       Accepted: Jun. 26, 2018;       Published: Jul. 18, 2018
DOI: 10.11648/j.iji.20180602.12      View  717      Downloads  52
Abstract
Many literatures reported that neonatal lupus erythematosus and its associated abnormalities mainly, cutaneous lupus lesions, congenital heart block (CHB), hematologic cytopenias, hepatobiliary disease and cardiomyopathy are associated with anti-Ro/SSA and anti-La/SSB antibodies. With skin findings occur in nearly 95% of NLE infants, others reported that 100% of NLE infants with CHB were positive for anti Ro/SSA antibodies and 90.2% of infants with skin NLE were positive for anti Ro/SSA. And long-term follow-up of children with neonatal lupus and their unaffected siblings revealed that 12.24% of NLE children identified definite rheumatic/autoimmune diseases after more than 8 years. Aim of the study: The aim of this study was to determine the incidence of positive anti-Ro/SSA and anti-La/SSB antibodies in infants with recurrent prolonged skin lesions and their mothers to determine asymptomatic mothers at risk to develop autoimmune disease. Subjects and methods: a total of 90 infants with recurrent prolonged skin lesions below the age of 6 months and their mothers attending pediatric screening and follow up clinic at Al Galaa Teaching Hospital in Cairo, Egypt were investigated for positivity of anti Ro/SSA and anti La/SSB antibodies using enzyme linked immunoassay (ELISA). Results: Incidence rate of positive anti Ro/SSA alone and anti La/SSB alone antibodies in infants were 34.4% and 23.3% respectively, and positive both anti Ro/SSA and anti La/SSB antibodies was 21.1%, while in their mothers, positive both anti Ro/SSA and anti La/SSB antibodies was 36.7%. Among the 33 cases with positive antibodies female: male ratio was 2.3:1, and rheumatologic and autoimmune diseases was positive in 14 (42.4%) mothers, while, 19 (57.6%) were asymptomatic mothers, anemia, lymphocytosis, neutropenia with relative lymphocytosis, eosinophilia and thrombocytopenia were found in 6.1%, 9.1%, 3.0%, 9.1% and 12.1% respectively. Liver transaminases were elevated in 4 (12.1%). Positive anti Ro/SSA and anti La/SSB antibodies were statistically significantly correlated with infant age, body weight, body length and head circumference, female sex, infants mothers’ rheumatologic and autoimmune diseases, distribution of skin lesions, positive history of steroid containing cream use, and thrombocytopenia. However, both antibodies showed no statistically significant correlation with infant feeding, rate of recurrent skin lesions, anemia, lymphocytosis, neutropenia with relative lymphocytosis, eosinophilia, positive CRP, and elevated ESR. Conclusion: our infant cases with prolonged skin lesions with positive anti Ro/SSA and anti La/SSB antibodies with their mothers’ especially asymptomatic ones should be investigated and followed up properly for development of NLE and autoimmune diseases.
Keywords
Anti Ro/SSA Antibody, Anti La/SSB Antibody, Cutaneous NLE, Autoimmune Diseases
To cite this article
Mona Sayed Aly Hassan Makhlouf, Suzan Fahim Ghobashy, Hanan Farouk Mohamed, Ikram Idris Alyan, Fawzy Aly Abualfadl, Incidence of Positive Anti-Ro/SSA and Anti-La/SSB Antibodies Among Infants with Prolonged Skin Lesions and Its Relation to Autoimmune Disease in the Mother, International Journal of Immunology. Vol. 6, No. 2, 2018, pp. 30-42. doi: 10.11648/j.iji.20180602.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Chan EK, Tan EM. Epitopic targets for autoantibodies in SLE and Sjögren’s syndrome. Curr Opin Rheumatol 1989; 1:376–81.
[2]
Ben-Chetrit E, Gandy BJ, Tan EM, et al. Isolation and characterization of cDNA clone encoding the 60 kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J Clin Invest 1989; 83:1284–92.
[3]
O’Brien CA, Margelot K, Wolin SE. Xenopus Ro ribonucleoproteins: members of an evolutionary conserved class of cytoplasmic ribonucleoproteins. Proc Natl Acad Sci USA 1993; 90:7250–4.
[4]
Meyer O. [Anti Ro/ SSA and anti La/ SSB antibodies. What's new?] 2004 Ann Med Interne (Paris). 2002 Dec; 153(8):520-9.
[5]
Silverman ED, Laxer RM. Neonatal lupus erythematosus. Rheum Dis Clin North Am. 1997; 23:599-618.
[6]
Dörner T, Feist E, Pruss A, Chaoui R, Göldner B, Hiepe E. Significance of autoantibodies in neonatal lupus erythematosus. Int Arch Allergy Immunol. 2000; 123:58-66.
[7]
Chakravarty EF, Colón I, Langen ES, Nix DA, El-Sayed YY, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005; 192: 1897-1904.
[8]
Nasef N, Hafez M, Bakr A. Neonatal lupus erythematosus. J Neonatol Clin Pediatr, 2014;77 (2): 82–86
[9]
Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678–83.
[10]
Sontheimer RD, Maddison PJ, Reichlin M, Jordan RE, Stastny P, Gilliam JN. Serologic and HLA associations of subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982; 97:664-671.
[11]
Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol. 1999; 40:675-681.
[12]
Wei Sun, Tian-Ming Yuan, Li-Hua Chen, and Hui-Min Yu: Neonatal Lupus Erythematosus: Three Case Reports and Review of the Chinese, Literature Clinical Pediatrics 2010; January 49(7) 627– 634
[13]
Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term follow-up of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002; 46: 2377-2383.
[14]
Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013; 382: 819–31.
[15]
Marcdante K, Kliegman RM, Behrman RE, Jenson HB. Nelson essentials of pediatrics: Elsevier Health Sciences; 2010.
[16]
Hon KL, Leung AKC. Neonatal Lupus Erythematosus. Autoimmune Dis. 2012; doi: 10. 1155/2012/301274.
[17]
Lee LA. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev. 2005; 4: 207–13.
[18]
Moroni G, Ponticelli C. Pregnancy in women with systemic lupus erythematosus (SLE). European journal of internal medicine. 2016; 32: 7-12.
[19]
Zuppa AA, Riccardi R, Frezza S, Gallini F, Luciano RMP, Alighieri G, et al. Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmunity Reviews. 2017. Autoimmun Rev. 2017; 16 (4):427-32.
[20]
Jakobsen I, Helmig R, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990–2010. Scandinavian journal of rheumatology. 2015;44(5):377-84.
[21]
Wei Q, Ouyang Y, Zeng W, Duan L, Ge J, Liao H. Pregnancy complicating systemic lupus erythematosus: a series of 86 cases. Archives of gynecology and obstetrics. 2011; 284 (5):1067-71.
[22]
Aggarwal N, Raveendran A, Suri V, Chopra S, Sikka P, Sharma A. Pregnancy outcome in systemic lupus erythematosus: Asia’s largest single centre study. Archives of gynecology and obstetrics. 2011; 284 (2):281-5.
[23]
Hendawy S, Abdel-Mohsen D, Ebrahim S, Ewais H, Moussa S, Khattab D, et al. Pregnancy related complications in patients with systemic lupus erythematosus, an Egyptian experience. Clinical medicine insights Reproductive health. 2011; 5: 17–24.
[24]
Singh AG, Chowdhary VR. Pregnancy‐related issues in women with systemic lupus erythematosus. International journal of rheumatic diseases. 2015; 18 (2):172-81.
[25]
Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. Journal of Thrombosis and Haemostasis. 2014; 12 (4): 452-8.
[26]
Clowse ME, Wallace DJ, Weisman M, James A, Criscione-Schreiber LG, Pisetsky DS. Predictors of preterm birth in patients with mild systemic lupus erythematosus. Annals of the rheumatic diseases. 2013; 72(9):1536-9.
[27]
Zhan Z, Yang Y, Zhan Y, Chen D, Liang L, Yang X. Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus. PLoS ONE 2017; 12(4): e0176457.
[28]
Karimi FZ, Saeidi M, Mirteimouri M, Maleki-Saghooni N. Maternal, Fetal and Neonatal Outcomes in Pregnant Women with Systemic Lupus Erythematosus: A Comprehensive Review Study. Int J Pediatr 2017; 5(11): 6151-71. DOI: 10. 22038/ijp. 2017. 24527. 2066
[29]
Dickey BZ, Holland KE, Drolet BA, Galbraith SS, Lyon VB, Siegel DH. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol. 2013 Aug. 169(2):428-33. [Medline].
[30]
Dörner T, Feist E, Chaoui R, Hiepe F. Enhanced frequency of autoimmune congenital heart block in female offspring. Rheumatology (Oxford) 1999; 38, 380–2.
[31]
Li YQ, Wang Q, Luo Y, Zhao Y. Neonatal lupus erythematosus: a review of 123 cases in China. Int J Rheum Dis. 2015; 18 (7):761–7.
[32]
[32]. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am 2005; 31, 299–313, vii.
[33]
Peñate Y, Luján D, Rodríguez J, Hernández-Machín B, Montenegro T, Afonso JL, et al. [Neonatal lupus erythematosus: 4 cases and clinical review]. Actas Dermosifiliogr. 2005 Dec. 96(10):690-6. [Medline].
[34]
Asboth D, Kassay E, Noll J, Szalai Z. Neonatal lupus erythematosus: deep and ulcerating form. Borgyogaszati Venerol Szemle. 2000;. 76:263-5.
[35]
Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124, 1927–35.
[36]
Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009; 68, 828–35.
[37]
Neinman AR, Lee LA, Weston WL, Buyon JB. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 142: 674–80.
[38]
Lee L. A., “Cutaneous lupus in infancy and childhood,” Lupus, 2010; vol. 19, no. 9, pp. 1112–1117.
[39]
Silverman E. and Jaeggi E., “Non-cardiac manifestations of neonatal lupus erythematosus,” Scandinavian Journal of Immunology, 2010; vol. 72, no. 3, pp. 223–225.
[40]
Chen YA, Tseng J, Yang M, Tsao Y, Lin H. Acute respiratory distress syndrome in a pregnant woman with systemic lupus erythematosus: a case report. Lupus. 2014; 23: 1528-32.
[41]
Buyon JP. Updates on lupus and pregnancy. Bulletin of the NYU hospital for joint diseases. 2009; 67 (3):271.
[42]
Al Arfaj A, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus. 2010; 19(14):1665-73.
[43]
Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon J-B, Dallay D, et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24(13):1384-91
[44]
Lv J, Wang W, Li Y. Clinical outcomes and predictors of fetal and maternal consequences of pregnancy in lupus nephritis patients. International urology and nephrology. 2015; 47 (8): 1379-85.
[45]
de Jesus GR M-PC, de Jesus NR, dos Santos FC, Klumb EM, Carrasco MG, et al. Understanding and managing pregnancy in patients with lupus. Autoimmune diseases. 2015; 20 (15):1-18.
[46]
Nili F, McLeod L, O’Connell C, Sutton E, McMillan D. Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a population-based study. Journal of Obstetrics and Gynaecology Canada. 2013; 35 (4):323-8.
[47]
Liu. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. 2012; 25(3):261-66.
[48]
Mokbel A, Geilan AM, AboElgheit S. Could women with systemic lupus erythematosus (SLE) have successful pregnancy outcomes? Prospective observational study. Egypt Rheumatol 2013; 35(3):133–139. doi: 10. 1016/j. ejr. 2013 .02. 002
[49]
Surita FG, Parpinelli MA, Yonehara E, Krupa F, Cecatti JG. Systemic lupus erythematosus and pregnancy: clinical evolution, maternal and perinatal outcomes and placental findings. Sao Paulo Med J 2007; 125: 91–5.
[50]
Chandran V, Aggarwal A, Misra R. Active disease during pregnancy is associated with poor fetal outcome in Indian patients with systemic lupus erythematosus. Rheumatol Int 2005; 26: 152–6.
[51]
Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 514.
[52]
Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33: 237.
[53]
Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al, for the PRIDE Investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485–93.
[54]
Klauninger R, Skog A, Horvath L, Winqvist O, Edner A, Bremme K, et al. Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus. 2009; 18: 792–8. [PubMed]
[55]
Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP. The presence of IgG antibodies reactive with components of the SSA/Ro- SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum 2002; 46: 269–271.
[56]
Rao L, Liu G, Li C, Li Y, Wang Z, Zhou Z, et al. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp Ther Med (2013) 5(6):1710–4. 10. 3892/etm. 2013. 1051 [PMC free article] [PubMed] [Cross Ref].
Browse journals by subject